CRISPR Therapeutics AG (NASDAQ:CRSP) Jefferies London Healthcare Conference November 20, 2024 11:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer and Chairman Conference Call Participants Maury Raycroft - Jefferies Maury Raycroft Hi, everyone. My name is Maury Raycroft, I'm one of the biotech analysts at Jeffreys. I'd like to welcome Sam Kulkarni, the CEO of CRISPR Therapeutics. Sam, thanks so much for joining us today. Samarth Kulkarni Thank you for having me. Maury Raycroft And we' ...

CRISPR Therapeutics’ (CRSP) shares have lost 6.6% in the past two weeks compared with the industry’s 8.4% decline, as seen in the chart below. The stock has underperformed the sector and the S&P 500 index. Shares of the company are also currently trading below its 50-day and 200-day moving averages.CRSP Stock Performance Image Source: Zacks Investment ResearchThe drop in the share price is likely due to the decline of the drug/biotech sector in the past couple of months due to lower-than-expected third-quar ...

Biotechs often need several years to realize their visions, even after they have a drug approved for the first time. There's typically plenty of upside in store for enterprising and patient investors.Here are two such opportunities that are ripe for buying today, provided that you're willing to hold on to your shares for at least five years.1. CRISPR TherapeuticsWith a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (CRSP 0.85%) has an impressive resume already, but i ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Samarth Kulkarni - CEO and Chairman Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay Good afternoon and thank you for joining us at Guggenheim's Inaugural Healthcare Innovations Conference. I am Debjit and one of the therapeutic analysts here. And joining me today is Samarth Kulkarni, CEO and Chairman of CRISPR Therapeutics. ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Samarth Kulkarni - CEO and Chairman Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay Good afternoon and thank you for joining us at Guggenheim's Inaugural Healthcare Innovations Conference. I am Debjit and one of the therapeutic analysts here. And joining me today is Samarth Kulkarni, CEO and Chairman of CRISPR Therapeutics. ...

CRISPR Therapeutics (CRSP -5.91%) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior successes to become a biotech powerhouse and prove to investors that it isn't a one-trick pony.The next three years will be critical for both of those things. Here's what to expect.This bird is leaving the nestBy late 2027, CRISPR will be a larger biotech, with much more revenue, more collaborators, and a much bi ...

ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:00 p.m. GMT. A live webcast of the fireside chat will be available on the "Events & Presentations" page ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Shares of CRISPR Therapeutics AG (CRSP) have gained 11.4% over the past four weeks to close the last trading session at $50.36, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $81.96 indicates a potential upside of 62.8%.The mean estimate comprises 24 short-term price targets with a standard deviation of $34.57. While the lowest estimate of $30 indicates a 40.4% decline from the ...

CRISPR Therapeutics (CRSP) incurred a third-quarter 2024 loss of $1.01 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.33. In the year-ago period, the company incurred a loss of $1.41 per share.Total revenues, though negligible, were entirely from grant revenues, which amounted to $0.6 million in the quarter. The reported figure significantly missed the Zacks Consensus Estimate of $6.4 million. CRSP did not generate revenues during the year-ago period.More on CRSP’s EarningsR ...